Last edition
News about Market
WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases
WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune disorders.
Market | 29/01/2026 | By News Bureau | 191
Boehringer and Simcere Partner on Dual-Target IBD Antibody
Boehringer Ingelheim has signed a licence and collaboration deal with Simcere to develop a novel TL1A/IL23p19 bispecific antibody for inflammatory bowel disease, gaining global rights outside greater China, with Simcere eligible for up to €1.058 billion in payments.
Market | 29/01/2026 | By News Bureau | 118
Davaindia Launches 77 New Stores Nationwide to Mark India's 77th Republic Day
The expansion by Zota Healthcare’s generic pharmacy chain strengthens access to affordable medicines across metros and Tier II and III cities under its “Har Ghar Ki Pharmacy” vision.
Market | 28/01/2026 | By News Bureau | 271
India's OTC Market Projected to Reach INR 98,000 Crore by 2030, EY Report Says
A new report by EY projects that India’s over-the-counter (OTC) drug market is expected to nearly double by 2030, reaching INR 98,000 crore, up from around INR 47,000 crore in 2024, growing at a compound annual growth rate of about 13 per cent.
Market | 28/01/2026 | By Darshana | 217
Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal
According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.
Market | 28/01/2026 | By News Bureau | 144
Merck Ends Acquisition Talks With Revolution Medicines
Merck has ended discussions to acquire cancer drug developer Revolution Medicines after the two sides failed to agree on valuation, according to reports. The talks, which had been ongoing for several weeks, were discontinued as differences over pricing could not be resolved.
Market | 27/01/2026 | By Darshana | 124
Mair Therapeutics and Radboud University Partner to Advance Parkinson's Therapy
Mair Therapeutics has entered into a scientific collaboration with Radboud University to advance the development of TMEM175 agonists for Parkinson’s disease, with Dr Marijn Kuijpers’ laboratory at the Donders Centre for Neuroscience evaluating a portfolio of TMEM175-targeting compounds developed by the company.
Market | 27/01/2026 | By News Bureau | 165
Syngene International reported a muted financial performance for the third quarter of FY26, with consolidated revenue declining three percent year on year to INR nine hundred thirty two crore, compared with INR nine hundred sixty two crore in the same quarter last year. Profit after tax, before exceptional items, stood at INR seventy three crore.
Market | 23/01/2026 | By Darshana | 526
Dr Reddy's Q3 FY26 Net Profit Falls Fourteen Percent Despite Revenue Growth
Dr Reddy’s Laboratories reported consolidated revenue of INR eight thousand seven hundred twenty seven crore in the third quarter of financial year twenty six, registering year on year growth.
Market | 23/01/2026 | By Darshana | 307
Zydus Launches World's First Nivolumab Biosimilar 'Tishtha' in India
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the immunotherapy drug nivolumab, in India, aimed at expanding access to advanced cancer care by offering the treatment at nearly one-fourth the cost of the reference product for patients with multiple cancer types.
Market | 23/01/2026 | By News Bureau | 595
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy